Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 4/20 | 0.40 |
| ▸ | CA2 | P00918 | 4/20 | 0.40 |
| ▸ | CA9 | Q16790 | 4/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 8/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6956240 | 0.92 | POLB (0.44) | POLBGAALMNACYP3A4CYP2C9 | |
| SCHEMBL6955423 | 0.88 | LMNA (0.43) | POLBGAALMNACYP3A4CYP2C9 | |
| SCHEMBL6953709 | 0.88 | LMNA (0.43) | POLBGAALMNACYP3A4CYP2C9 | |
| SCHEMBL6945517 | 0.88 | LMNA (0.43) | POLBGAALMNACYP3A4CYP2C9 | |
| SCHEMBL6950961 | 0.88 | LMNA (0.43) | POLBGAALMNACYP3A4CYP2C9 | |
| SCHEMBL3546641 | 0.88 | LMNA (0.43) | POLBGAALMNACYP3A4CYP2C9 | |
| SCHEMBL6952973 | 0.85 | LMNA (0.41) | POLBGAALMNACYP3A4CYP2C9 | |
| SCHEMBL6952185 | 0.85 | LMNA (0.41) | POLBGAALMNACYP3A4CYP2C9 | |
| SCHEMBL6952010 | 0.84 | LMNA (0.41) | POLBGAALMNACYP3A4CYP2C9 | |
| SCHEMBL6947607 | 0.84 | LMNA (0.41) | POLBGAALMNACYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0994890-B1 | BENZIMIDAZOLE DERIVATIVES | GLAXO GROUP LTD (GB) | 2003-08-06 | — | — | EP | disclosed |
| US-6455507-B1 | E.G., 2-BROMO-5,6-DICHLORO-1-BETA-D-RIBOPYRANOSYL-1H-BENZIMIDAZOLE; VIRICIDES, ESPECIALLY INFECTIONS OF HERPES AND CYTOMEGALO VIRUSES | SMITHKLINE BEECHAM CORPORATION | 2002-09-24 | — | — | US | disclosed |
| US-20020094963-A1 | BENZIMIDAZOLE DERIVATIVES | GLAXO WELLCOME INC. | 2002-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094963-A1 | BENZIMIDAZOLE DERIVATIVES | ZC3HAV1, BRPF3, BRD3 | POLB 1342/4885GAA 235/4885LMNA 3060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.